Clinical Trials at University of Oklahoma Health Sciences Center

As of August 2026, 180 paid clinical trials are recruiting at University of Oklahoma Health Sciences Center, located at 1200 N PHILLIPS AVE, SUITE 12109, OKLAHOMA CITY, OK 73104-4600, phone (405) 271-8685 in Oklahoma City, Oklahoma. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

View the full facility profile →

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: August 27, 2026.

Filter results

Filter results

State

City

Facility

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

180 clinical trials at University of Oklahoma Health Sciences Center

·Clear filters·

Get a weekly email when new trials open in Oklahoma City, OK.

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

for Muscle Invasive Bladder Urothelial Carcinoma

Sites in Oklahoma City +207 more locations

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT07097142·Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

for Ovarian Carcinoma

Sites in Oklahoma City +480 more locations

Sponsor: NRG Oncology

Sex: Female·Age: 35 - 50

Code: NCT04251052·Recruiting·Listed Jan 2020

Apply to this trial

E-Mindfulness Approaches for Living After Breast Cancer

for Breast Cancer

Sites in Oklahoma City +373 more locations

Sponsor: NRG Oncology

Sex: All·Age: 18 - 50

Code: NCT06748222·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

for Advanced Malignant Solid Neoplasm

Sites in Oklahoma City +430 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: All ages

Code: NCT05564377·Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

for Metastatic Renal Cell Carcinoma

Sites in Oklahoma City, Tulsa +278 more locations

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05327686·Phase 2·Recruiting·Listed Apr 2022

Apply to this trial

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

for Advanced Esophageal Adenocarcinoma

Drug: Nivolumab

Sites in Oklahoma City, Lawton +336 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06203600·Phase 2, Phase 3·Recruiting·Listed Jan 2024

Apply to this trial

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for Acute Myeloid Leukemia

Sites in Oklahoma City +329 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05564390·Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

for Refractory Differentiated Thyroid Gland Carcinoma

Sites in Oklahoma City, Lawton +284 more locations

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT06475989·Phase 3·Recruiting·Listed Jun 2024

Apply to this trial

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

for Mantle Cell Lymphoma

Sites in Oklahoma City, Lawton +228 more locations

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 60+

Code: NCT05976763·Phase 3·Recruiting·Listed Aug 2023

Apply to this trial

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

for Clinical Stage III Cutaneous Melanoma AJCC v8

Drug: Cabozantinib

Sites in Oklahoma City +207 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05136196·Phase 2·Recruiting·Listed Nov 2021

Apply to this trial

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

for Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Drug: Nivolumab

Sites in Oklahoma City, Tulsa +378 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 5 - 60

Code: NCT05675410·Phase 3·Recruiting·Listed Jan 2023

Apply to this trial

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

for Classic Follicular Lymphoma

Drug: Mosunetuzumab

Sites in Oklahoma City +252 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06337318·Phase 3·Recruiting·Listed Mar 2024

Apply to this trial

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

for Anaplastic Large Cell Lymphoma, ALK-Negative

Sites in Oklahoma City +141 more locations

Sponsor: Eastern Cooperative Oncology Group

Sex: All·Age: 18 - 75

Code: NCT06724237·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

for Lung Non-Small Cell Carcinoma

Sites in Oklahoma City +265 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06498635·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

for Renal Pelvis and Ureter Urothelial Carcinoma

Drug: Durvalumab

Sites in Oklahoma City, Lawton +151 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04628767·Phase 2, Phase 3·Recruiting·Listed Nov 2020

Apply to this trial

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

for Muscle Invasive Bladder Urothelial Carcinoma

Sites in Oklahoma City +152 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT07061964·Phase 2·Recruiting·Listed Jul 2025

Apply to this trial

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

Sites in Oklahoma City +205 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 59

Code: NCT05554406·Phase 2·Recruiting·Listed Sep 2022

Apply to this trial

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

Drug: Venetoclax

Sites in Oklahoma City +215 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06317649·Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

for Myelodysplastic Syndrome

Sites in Oklahoma City +137 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06577441·Phase 2·Recruiting·Listed Aug 2024

Apply to this trial

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

for Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Sites in Oklahoma City +145 more locations

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06532279·Phase 2·Recruiting·Listed Aug 2024

Apply to this trial

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

Drug: Venetoclax

Sites in Oklahoma City +168 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 59

Code: NCT05554393·Phase 2·Recruiting·Listed Sep 2022

Apply to this trial

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

for Hematopoietic and Lymphatic System Neoplasm

Sites in Oklahoma City +190 more locations

Sponsor: Children's Oncology Group

Sex: Female·Age: Up to 39

Code: NCT06513962·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

for Advanced Lung Non-Small Cell Carcinoma

Drug: Osimertinib

Sites in Oklahoma City +219 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT03191149·Phase 2·Recruiting·Listed Jun 2017

Apply to this trial

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

for Metastatic Salivary Gland Carcinoma

Sites in Oklahoma City, Lawton +140 more locations

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05408845·Phase 2·Recruiting·Listed Jun 2022

Apply to this trial

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

for Prostate Cancer (Adenocarcinoma)

Sites in Oklahoma City, Lawton +357 more locations

Sponsor: Canadian Cancer Trials Group

Sex: Male·Age: 18+

Code: NCT06592924·Phase 3·Recruiting·Listed Sep 2024

Apply to this trial

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

for Anatomic Stage IV Breast Cancer AJCC v8

Sites in Oklahoma City +256 more locations

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06500455·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

Sites in Oklahoma City +128 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06672146·Phase 2·Recruiting·Listed Nov 2024

Apply to this trial

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

for Locally Advanced Urothelial Carcinoma

Sites in Oklahoma City +158 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06524544·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

for Castration-Sensitive Prostate Carcinoma

Drug: Apalutamide

Sites in Oklahoma City +194 more locations

Sponsor: Alliance for Clinical Trials in Oncology

Sex: Male·Age: 18+

Code: NCT06931340·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

for Non-Muscle Invasive Bladder Urothelial Carcinoma

Sites in Oklahoma City +130 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06770582·Phase 2·Recruiting·Listed Jan 2025

Apply to this trial

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

for B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

Sites in Oklahoma City +81 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT03739814·Phase 2·Recruiting·Listed Nov 2018

Apply to this trial

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

for Metastatic Dedifferentiated Liposarcoma

Sites in Oklahoma City +236 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06422806·Phase 3·Recruiting·Listed May 2024

Apply to this trial

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

for Malignant Female Reproductive System Neoplasm

Sites in Oklahoma City +177 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06126276·Phase 2·Recruiting·Listed Nov 2023

Apply to this trial

The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

for Atrial Fibrillation

Sites in Oklahoma City +86 more locations

Sponsor: Johns Hopkins University

Sex: All·Age: 22 - 85

Code: NCT05836987·Phase 3·Recruiting·Listed May 2023

Apply to this trial

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

for Locally Advanced Adrenal Cortical Carcinoma

Drug: Cabozantinib

Sites in Oklahoma City +78 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 12+

Code: NCT06900595·Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

for Endometrial Adenocarcinoma

Drug: Ipilimumab

Sites in Oklahoma City, Tulsa +123 more locations

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT05112601·Phase 2·Recruiting·Listed Nov 2021

Apply to this trial

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

for B Acute Lymphoblastic Leukemia

Sites in Oklahoma City, Tulsa +185 more locations

Sponsor: Children's Oncology Group

Sex: All·Age: 365 Days - 25

Code: NCT03959085·Phase 3·Recruiting·Listed May 2019

Apply to this trial

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

for Plasma Cell Myeloma

Sites in Oklahoma City +388 more locations

Sponsor: SWOG Cancer Research Network

Sex: All·Age: All ages

Code: NCT05561387·Phase 3·Recruiting·Listed Sep 2022

Apply to this trial

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

for Previously Treated Non-Small Cell Lung Cancer

Sites in Oklahoma City, Lawton +948 more locations

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT03851445·Phase 2, Phase 3·Recruiting·Listed Feb 2019

Apply to this trial

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

for Acute Myeloid Leukemia

Sites in Oklahoma City +168 more locations

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 21

Code: NCT04293562·Phase 3·Recruiting·Listed Mar 2020

Apply to this trial